

CHAPTER- 7

REFERENCES

References:

- Abrahamsson, P.-A. (1999). Neuroendocrine differentiation in prostatic carcinoma. *The Prostate*, 39(2), 135–148. [https://doi.org/10.1002/\(SICI\)1097-0045\(19990501\)39:2<135::AID-PROS9>3.0.CO;2-S](https://doi.org/10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S)
- Ali, A., & Kulik, G. (2021). Signaling Pathways That Control Apoptosis in Prostate Cancer. *Cancers*, 13(5), 937. <https://doi.org/10.3390/cancers13050937>
- Aljofan, M., & Riethmacher, D. (2019). Anticancer activity of metformin: A systematic review of the literature. *Future Science OA*, 5(8), FSO410. <https://doi.org/10.2144/fsoa-2019-0053>
- Amorino, G. P., Deeble, P. D., & Parsons, S. J. (2007). Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. *Oncogene*, 26(5), 745–756. <https://doi.org/10.1038/sj.onc.1209814>
- Ashrafizadeh, M., Paskeh, M. D. A., Mirzaei, S., Gholami, M. H., Zarrabi, A., Hashemi, F., Hushmandi, K., Hashemi, M., Nabavi, N., Crea, F., Ren, J., Klionsky, D. J., Kumar, A. P., & Wang, Y. (2022). Targeting autophagy in prostate cancer: Preclinical and clinical evidence for therapeutic response. *Journal of Experimental & Clinical Cancer Research*, 41(1), 105. <https://doi.org/10.1186/s13046-022-02293-6>
- Bonkhoff, H., & Remberger, K. (1993). Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. *Virchows Archiv A Pathological Anatomy and Histopathology*, 422(1), 35–38. <https://doi.org/10.1007/BF01605130>
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, caac.21834. <https://doi.org/10.3322/caac.21834>
- Budukh, A., Thakur, J., Dora, T., Kadam, P., Bagal, S., Patel, K., Goel, A., Sancheti, S., Gulia, A., Chaturvedi, P., Dikshit, R., & Badwe, R. (2023). Overall survival of prostate cancer from Sangrur and Mansa cancer registries of Punjab state, India. *Indian Journal of Urology*, 39(2), 148. https://doi.org/10.4103/iju.iju_38_23
- Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015). Mechanisms of resistance in castration-resistant prostate cancer. *Translational Andrology and Urology*, 4(3).
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004). Molecular determinants of resistance to antiandrogen therapy. *Nature Medicine*, 10(1), 33–39. <https://doi.org/10.1038/nm972>
- Chen, J., Liu, J., Lei, Y., & Liu, M. (2019). The anti-inflammation, anti-oxidative and anti-fibrosis properties of swertiamarin in cigarette smoke exposure-induced prostate dysfunction in rats. *Aging*, 11(22), 10409–10421. <https://doi.org/10.18632/aging.102467>

Chen, M., Tanner, M., Levine, A. C., Levina, E., Ohouo, P. Y., & Buttyan, R. (2009). Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. *Cell Cycle*, 8(1), 149–157. <https://doi.org/10.4161/cc.8.1.7532>

Chen, Y., Sawyers, C. L., & Scher, H. I. (2008). Targeting the androgen receptor pathway in prostate cancer. *Current Opinion in Pharmacology*, 8(4), 440–448. <https://doi.org/10.1016/j.coph.2008.07.005>

Clark, J. P., & Cooper, C. S. (2009). ETS gene fusions in prostate cancer. *Nature Reviews Urology*, 6(8), 429–439. <https://doi.org/10.1038/nrurol.2009.127>

Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. *Nature Medicine*, 5(3), 280–285. <https://doi.org/10.1038/6495>

Crona, D., & Whang, Y. (2017). Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. *Cancers*, 9(12), 67. <https://doi.org/10.3390/cancers9060067>

Dalal, K., Roshan-Moniri, M., Sharma, A., Li, H., Ban, F., Hessein, M., Hsing, M., Singh, K., LeBlanc, E., Dehm, S., Tomlinson, G., E. S., Cherkasov, A., & Rennie, P. S. (2014). Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer. *Journal of Biological Chemistry*, 289(38), 26417–26429. <https://doi.org/10.1074/jbc.M114.553818>

De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007). Inflammation in prostate carcinogenesis. *Nature Reviews Cancer*, 7(4), 256–269. <https://doi.org/10.1038/nrc2090>

Department of Cell Biology, Histology and Pharmacology, University of Valladolid, Soria, Spain, Fernández-Lázaro, D., Fernández-Lázaro, C. I., Department of Cell Biology, Histology and Pharmacology, University of Valladolid, Soria, Spain, Córdoba, M. A., & Department Physiology. Faculty of Physiotherapy, University of Valladolid, Soria, Spain. (2018). Cell Death: Mechanisms and Pathways in Cancer Cells. *Cancer Medicine Journal*, 1(1), 12–23. <https://doi.org/10.46619/Cmj.2018.1-1003>

Dewhirst, M. W., Cao, Y., & Moeller, B. (2008). Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. *Nature Reviews Cancer*, 8(6), 425–437. <https://doi.org/10.1038/nrc2397>

Dillard, P. R., Lin, M.-F., & Khan, S. A. (2008). Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. *Molecular and Cellular Endocrinology*, 295(1–2), 115–120. <https://doi.org/10.1016/j.mce.2008.08.013>

Donkervoort, T., Sterling, A., Van Ness, J., & Donker, P. J. (1977). A Clinical and Urodynamic Study of Tadenan in the Treatment of Benign Prostatic Hypertrophy. *European Urology*, 3(4), 218–225. <https://doi.org/10.1159/000472101>

- England, K., & Cotter, T. G. (2005). Direct oxidative modifications of signalling proteins in mammalian cells and their effects on apoptosis. *Redox Report*, *10*(5), 237–245. <https://doi.org/10.1179/135100005X70224>
- Furic, L., Lawrence, M. G., & Risbridger, G. P. (2015). Pro-tumorigenic role of ER α in prostate cancer cells. *Aging*, *7*(6), 356–357. <https://doi.org/10.18632/aging.100769>
- Guarnaccia, L., Marfia, G., Masseroli, M., Navone, S., Balsamo, M., Caroli, M., Valtorta, S., Moresco, R., Campanella, R., Garzia, E., Riboni, L., & Locatelli, M. (2021). Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma. *Cancers*, *14*, 112. <https://doi.org/10.3390/cancers14010112>
- Haffner, J., Potiron, E., Bouyé, S., Puech, P., Leroy, X., Lemaitre, L., & Villers, A. (2009). Peripheral zone prostate cancers: Location and intraprostatic patterns of spread at histopathology. *The Prostate*, *69*(3), 276–282. <https://doi.org/10.1002/pros.20881>
- He, L., & Wondisford, F. E. (2015). Metformin Action: Concentrations Matter. *Cell Metabolism*, *21*(2), 159–162. <https://doi.org/10.1016/j.cmet.2015.01.003>
- He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022). Targeting signaling pathways in prostate cancer: Mechanisms and clinical trials. *Signal Transduction and Targeted Therapy*, *7*(1), 198. <https://doi.org/10.1038/s41392-022-01042-7>
- Hofland, J., Van Weerden, W. M., Dits, N. F. J., Steenbergen, J., Van Leenders, G. J. L. H., Jenster, G., Schröder, F. H., & De Jong, F. H. (2010). Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate Cancer. *Cancer Research*, *70*(3), 1256–1264. <https://doi.org/10.1158/0008-5472.CAN-09-2092>
- Ikhlas, S., & Ahmad, M. (2017). Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways. *Life Sciences*, *185*, 53–62. <https://doi.org/10.1016/j.lfs.2017.07.029>
- Kim, J., Lee, J., Jang, S. Y., Kim, C., Choi, Y., & Kim, A. (2016). Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. *Oncology Reports*, *35*(5), 2553–2560. <https://doi.org/10.3892/or.2016.4675>
- Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., Adihetty, P. J., Adler, S. G., Agam, G., Agarwal, R., Aghi, M. K., Agnello, M., Agostinis, P., Aguilar, P. V., Aguirre-Ghiso, J., ... Zughaier, S. M. (2016). Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, *12*(1), 1–222. <https://doi.org/10.1080/15548627.2015.1100356>
- Kumaraswamy, A., Welker Leng, K. R., Westbrook, T. C., Yates, J. A., Zhao, S. G., Evans, C. P., Feng, F. Y., Morgan, T. M., & Alumkal, J. J. (2021). Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. *European Urology*, *80*(1), 71–81. <https://doi.org/10.1016/j.eururo.2021.03.005>

- Kweldam, C. F., Van Leenders, G. J., & Van Der Kwast, T. (2019). Grading of prostate cancer: A work in progress. *Histopathology*, *74*(1), 146–160. <https://doi.org/10.1111/his.13767>
- Lee, H.-R., Hwang, K.-A., & Choi, K.-C. (2014). The estrogen receptor signaling pathway activated by phthalates is linked with transforming growth factor- β in the progression of LNCaP prostate cancer models. *International Journal of Oncology*, *45*(2), 595–602. <https://doi.org/10.3892/ijo.2014.2460>
- Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009). New Users of Metformin Are at Low Risk of Incident Cancer. *Diabetes Care*, *32*(9), 1620–1625. <https://doi.org/10.2337/dc08-2175>
- Ling, S., Tian, Y., Zhang, H., Jia, K., Feng, T., Sun, D., Gao, Z., Xu, F., Hou, Z., Li, Y., & Wang, L. (2014). Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel-7402/5-fluorouracil cells. *Molecular Medicine Reports*, *10*(6), 2891–2897. <https://doi.org/10.3892/mmr.2014.2614>
- Liu, G., Pei, F., Yang, F., Li, L., Amin, A., Liu, S., Buchan, J., & Cho, W. (2017). Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. *International Journal of Molecular Sciences*, *18*(2), 367. <https://doi.org/10.3390/ijms18020367>
- Long, R. M., Morrissey, C., Fitzpatrick, J. M., & Watson, R. W. G. (2005). Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. *Clinical Science*, *108*(1), 1–11. <https://doi.org/10.1042/CS20040241>
- Lu, J. P., Monardo, L., Bryskin, I., Hou, Z. F., Trachtenberg, J., Wilson, B. C., & Pinthus, J. H. (2010). Androgens induce oxidative stress and radiation resistance in prostate cancer cells through NADPH oxidase. *Prostate Cancer and Prostatic Diseases*, *13*(1), 39–46. <https://doi.org/10.1038/pcan.2009.24>
- Marjanovic, M. S. M., Vucicevic, L. M., Despotovic, A. R., & Stamenkovic, M. M. (n.d.). *Dual anticancer role of metformin: An old drug regulating AMPK dependent/independent pathways in metabolic, oncogenic/tumorsuppressing and immunity context.*
- McNeal, J. E. (1969). Origin and development of carcinoma in the prostate. *Cancer*, *23*(1), 24–34. [https://doi.org/10.1002/1097-0142\(196901\)23:1<24::AID-CNCR2820230103>3.0.CO;2-1](https://doi.org/10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1)
- Mondal, D., Narwani, D., Notta, S., Ghaffar, D., Mardhekar, N., & Quadri, S. S. A. (2020). Oxidative stress and redox signaling in CRPC progression: Therapeutic potential of clinically-tested Nrf2-activators. *Cancer Drug Resistance*. <https://doi.org/10.20517/cdr.2020.71>
- Mosli, H. H., Esmat, A., Atawia, R. T., Shoieb, S. M., Mosli, H. A., & Abdel-Naim, A. B. (2015). Metformin Attenuates Testosterone-Induced Prostatic Hyperplasia in Rats: A Pharmacological Perspective. *Scientific Reports*, *5*(1), 15639. <https://doi.org/10.1038/srep15639>
- Muhamad Fadzil, N. S., Sekar, M., Gan, S. H., Bonam, S. R., Wu, Y. S., Vaijanathappa, J., Ravi,

S., Lum, P. T., & Dhadde, S. B. (2021). Chemistry, Pharmacology and Therapeutic Potential of Swertiamarin – A Promising Natural Lead for New Drug Discovery and Development. *Drug Design, Development and Therapy, Volume 15*, 2721–2746.

<https://doi.org/10.2147/DDDT.S299753>

Nientiedt, C., Heller, M., Endris, V., Volckmar, A.-L., Zschäbitz, S., Tapia-Laliena, M. A., Duensing, A., Jäger, D., Schirmacher, P., Sültmann, H., Stenzinger, A., Hohenfellner, M., Grüllich, C., & Duensing, S. (2017). Mutations in BRCA2 and taxane resistance in prostate cancer. *Scientific Reports, 7*(1), 4574. <https://doi.org/10.1038/s41598-017-04897-x>

Noubissi Nzeteu, G. A., Geismann, C., Arlt, A., Hoogwater, F. J. H., Nijkamp, M. W., Meyer, N. H., & Bockhorn, M. (2022). Role of Epithelial-to-Mesenchymal Transition for the Generation of Circulating Tumors Cells and Cancer Cell Dissemination. *Cancers, 14*(22), 5483.

<https://doi.org/10.3390/cancers14225483>

O’Sullivan, R. J., & Karlseder, J. (2010). Telomeres: Protecting chromosomes against genome instability. *Nature Reviews Molecular Cell Biology, 11*(3), 171–181.

<https://doi.org/10.1038/nrm2848>

Ouyang, L., Shi, Z., Zhao, S., Wang, F. -T., Zhou, T. -T., Liu, B., & Bao, J. -K. (2012). Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis. *Cell Proliferation, 45*(6), 487–498. <https://doi.org/10.1111/j.1365-2184.2012.00845.x>

Packer, J. R., & Maitland, N. J. (2016). The molecular and cellular origin of human prostate cancer. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1863*(6), 1238–1260.

<https://doi.org/10.1016/j.bbamcr.2016.02.016>

Patel, P. G., Wessel, T., Kawashima, A., Okello, J. B. A., Jamaspishvili, T., Guérard, K., Lee, L., Lee, A. Y., How, N. E., Dion, D., Scarlata, E., Jackson, C. L., Boursalieu, S., Sack, T., Dunn, R., Moussa, M., Mackie, K., Ellis, A., Marra, E., ... Berman, D. M. (2019). A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer. *The Prostate, 79*(14), 1705–1714. <https://doi.org/10.1002/pros.23895>

Patel, T. P., Rawal, K., Soni, S., & Gupta, S. (2016). Swertiamarin ameliorates oleic acid induced lipid accumulation and oxidative stress by attenuating gluconeogenesis and lipogenesis in hepatic steatosis. *Biomedicine & Pharmacotherapy, 83*, 785–791.

<https://doi.org/10.1016/j.biopha.2016.07.028>

Patel, T. P., Soni, S., Parikh, P., Gosai, J., Chruvattil, R., & Gupta, S. (2013). Swertiamarin: An Active Lead from *Encostemma littorale* Regulates Hepatic and Adipose Tissue Gene Expression by Targeting PPAR- γ and Improves Insulin Sensitivity in Experimental NIDDM Rat Model. *Evidence-Based Complementary and Alternative Medicine, 2013*, 1–11.

<https://doi.org/10.1155/2013/358673>

Pernicova, I., & Korbonits, M. (2014). Metformin—Mode of action and clinical implications for diabetes and cancer. *Nature Reviews Endocrinology, 10*(3), 143–156.

<https://doi.org/10.1038/nrendo.2013.256>

Petrow, V., Padilla, G. M., Mukherji, S., & Marts, S. A. (2011). Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone. *Journal of Pharmacy and Pharmacology*, *36*(5), 352–353. <https://doi.org/10.1111/j.2042-7158.1984.tb04395.x>

Prins, G. S. (2008). Endocrine disruptors and prostate cancer risk. *Endocrine Related Cancer*, *15*(3), 649–656. <https://doi.org/10.1677/ERC-08-0043>

Quintero, J. C., Díaz, N. F., Rodríguez-Dorantes, M., & Camacho-Arroyo, I. (2023). Cancer Stem Cells and Androgen Receptor Signaling: Partners in Disease Progression. *International Journal of Molecular Sciences*, *24*(20), 15085. <https://doi.org/10.3390/ijms242015085>

Radmayr, C., Lunacek, A., Schwentner, C., Oswald, J., Klocker, H., & Bartsch, G. (2008). 5-alpha-reductase and the development of the human prostate. *Indian Journal of Urology*, *24*(3), 309. <https://doi.org/10.4103/0970-1591.42610>

Reddy, V., Iskander, A., Hwang, C., Divine, G., Menon, M., Barrack, E. R., Reddy, G. P.-V., & Kim, S.-H. (2019). Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death. *PLOS ONE*, *14*(5), e0211090. <https://doi.org/10.1371/journal.pone.0211090>

Rieckhoff, J., Meyer, F., Classen, S., Zielinski, A., Riepen, B., Wikman, H., Petersen, C., Rothkamm, K., Borgmann, K., & Parpys, A. C. (2020). Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization Against PARP1 Inhibition in a Replication-Dependent Manner. *Cancers*, *12*(10), 2809. <https://doi.org/10.3390/cancers12102809>

Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., Beltran, H., Abida, W., Bradley, R. K., Vinson, J., Cao, X., Vats, P., Kunju, L. P., Hussain, M., Feng, F. Y., ... Chinnaiyan, A. M. (2015). Integrative Clinical Genomics of Advanced Prostate Cancer. *Cell*, *162*(2), 454. <https://doi.org/10.1016/j.cell.2015.06.053>

Saraon, P., Jarvi, K., & Diamandis, E. P. (2011). Molecular Alterations during Progression of Prostate Cancer to Androgen Independence. *Clinical Chemistry*, *57*(10), 1366–1375. <https://doi.org/10.1373/clinchem.2011.165977>

Schroeder, A., Herrmann, A., Cherryholmes, G., Kowolik, C., Buettner, R., Pal, S., Yu, H., Müller-Newen, G., & Jove, R. (2014). Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling. *Cancer Research*, *74*(4), 1227–1237. <https://doi.org/10.1158/0008-5472.CAN-13-0594>

Shen, M. M., & Abate-Shen, C. (2010). Molecular genetics of prostate cancer: New prospects for old challenges. *Genes & Development*, *24*(18), 1967–2000. <https://doi.org/10.1101/gad.1965810>

Siddiqui, M., Mukherjee, S., Manivannan, P., & Malathi, K. (2015). RNase L Cleavage Products

Promote Switch from Autophagy to Apoptosis by Caspase-Mediated Cleavage of Beclin-1. *International Journal of Molecular Sciences*, 16(8), 17611–17636. <https://doi.org/10.3390/ijms160817611>

Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. *CA: A Cancer Journal for Clinicians*, 73(1), 17–48. <https://doi.org/10.3322/caac.21763>

Skuli, S. J., Alomari, S., Gaitsch, H., Bakayoko, A., Skuli, N., & Tyler, B. M. (2022). Metformin and Cancer, an Ambiguanidous Relationship. *Pharmaceuticals*, 15(5), 626. <https://doi.org/10.3390/ph15050626>

Song, I., Han, J., & Lee, H. K. (2015). Metformin as an anticancer drug: A Commentary on the metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. *Journal of Diabetes Investigation*, 6(5), 516–518. <https://doi.org/10.1111/jdi.12300>

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>

Tannock, I. F., Horti, J., Oudard, S., James, N. D., & Rosenthal, M. A. (2004). Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. *The New England Journal of Medicine*.

The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. *Nature Genetics*, 45(10), 1113–1120. <https://doi.org/10.1038/ng.2764>

Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018). Genetics and biology of prostate cancer. *Genes & Development*, 32(17–18), 1105–1140. <https://doi.org/10.1101/gad.315739.118>

Wang, X., & Wang, T. (2021). Swertiamarin exerts anticancer effects on human cervical cancer cells via induction of apoptosis, inhibition of cell migration and targeting of MEK-ERK pathway. *Tropical Journal of Pharmaceutical Research*, 20(1), 75–81. <https://doi.org/10.4314/tjpr.v20i1.12>

Xie, Y., Wang, L., Khan, M. A., Hamburger, A. W., Guang, W., Passaniti, A., Munir, K., Ross, D. D., Dean, M., & Hussain, A. (2021). Metformin and Androgen Receptor-Axis-Targeted (ARAT) Agents Induce Two PARP-1-Dependent Cell Death Pathways in Androgen-Sensitive Human Prostate Cancer Cells. *Cancers*, 13(4), 633. <https://doi.org/10.3390/cancers13040633>

Zhao, Y., Zeng, X., Tang, H., Ye, D., & Liu, J. (2019). Combination of metformin and paclitaxel suppresses proliferation and induces apoptosis of human prostate cancer cells via oxidative stress and targeting the mitochondria-dependent pathway. *Oncology Letters*. <https://doi.org/10.3892/ol.2019.10119>

Zhou, X., An, B., Lin, Y., Ni, Y., Zhao, X., & Liang, X. (2023). Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies. *Biomedicine & Pharmacotherapy*, *165*, 115036. <https://doi.org/10.1016/j.biopha.2023.115036>

Zhou, Y., Bolton, E. C., & Jones, J. O. (2015). Androgens and androgen receptor signaling in prostate tumorigenesis. *Journal of Molecular Endocrinology*, *54*(1), R15–R29. <https://doi.org/10.1530/JME-14-0203>

Zhu, Y., Mo, M., Wei, Y., Wu, J., Pan, J., Freedland, S. J., Zheng, Y., & Ye, D. (2021). Epidemiology and genomics of prostate cancer in Asian men. *Nature Reviews Urology*, *18*(5), 282–301. <https://doi.org/10.1038/s41585-021-00442-8>

Zou, G., Bai, J., Li, D., & Chen, Y. (2019). Effect of metformin on the proliferation, apoptosis, invasion and autophagy of ovarian cancer cells. *Experimental and Therapeutic Medicine*. <https://doi.org/10.3892/etm.2019.7803>